CommonMind Consortium

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: Common Mind Consortium
  • Initiator Type: Third-party organization
  • Disease focus:
    Bipolar Disorder, Schizophrenia
  • Location: North America


The CommonMind Consortium is a public-private precompetitive partnership that brings together disease area expertise, large-scale and well-curated brain sample collections, and data management and analysis expertise. A consortium goal is to generate and analyze large-scale genomic data from human subjects with neuropsychiatric disease and to make these data and the associated analytical results broadly available to the public.


As many as 450 million people worldwide are believed to be living with a mental or behavioral disorder: schizophrenia and bipolar disorder are two of the top six leading causes of years lived with disability according to the World Health Organization. The burden on the individual as well as on society is significant, with estimates for the healthcare costs for these individuals as high as 4 percent of the gross national product, which highlights a grave need for new therapies to alleviate suffering.

Technology has reached a level of maturity where generation of large-scale molecular data is feasible, enabling a better understanding of the molecular underpinnings of these disorders. CommonMind consists of a multifaceted team with expertise in the generation, management, and analysis of these data.

A central tenant of this project is that biological insights stemming from integrative genomic analysis are most compelling when they leverage the expertise across multiple disciplines and provide a transparent, reproducible description of analytical process. As such, the consortium has committed to making all data, analytical results, and methodological source code available to the public. The goal is to provide the opportunity for researchers to assess the quality of the data and results in order to (a) estimate the likelihood of our biological conclusions and (b) determine the most meaningful way to incorporate these findings into their own research.

Public release of data takes place through the Sage Bionetworks Synapse system and the database of Genotypes and Phenotypes (dbGAP). A description of current data-generation efforts can be found under the Data Generation tab of the consortium’s website, where links to public releases are posted.


Members participate in the consortium by providing funding or in kind data or samples. A modular design will be used to expand scope according to funding.

Points of Contact

Sponsors & Partners

Duke University

F. Hoffman-La Roche Ltd

Mount Sinai School of Medicine

National Institute of Mental Health

Sage Bionetworks

Takeda Pharmaceuticals Company Limited

University of North Carolina

University of Pennsylvania

University of Pittsburgh

Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.